Novel vitamin D3 analogs, 1α, 25(OH)2D3-26, 23-lactam (DLAMs), antagonize bone resorption via suppressing RANKL expression in osteoblasts

Biochemical and Biophysical Research Communications

Volumn 372, Issue 3, 2008, Pages 434-439

  Inada, Masaki ^a   Tsukamoto, Kazuki ^a   Hirata, Michiko ^a   Takita, Morichika ^a   Nagasawa, Kazuo ^a   Miyaura, Chisato ^a  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

Author keywords

1 , 25(OH)2D3 26, 23 lactam; Bone; Bone resorption; Osteoclast; Vitamin D

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; CALCITRIOL 26,23 LACTONE; COLECALCIFEROL DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; VITAMIN D RECEPTOR; BONE DENSITY CONSERVATION AGENT; CALCITRIOL RECEPTOR; COLECALCIFEROL; DRUG DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CALVARIA; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOSE RESPONSE; MOUSE; NEWBORN; NONHUMAN; ORGAN CULTURE; OSTEOBLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; MOUSE STRAIN; ORGAN CULTURE TECHNIQUE; OSTEOCLAST; PROTEIN FOLDING; PROTEIN SECONDARY STRUCTURE; STEREOISOMERISM; SYNTHESIS;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CHOLECALCIFEROL; MICE; MICE, INBRED STRAINS; ORGAN CULTURE TECHNIQUES; OSTEOBLASTS; OSTEOCLASTS; PROTEIN FOLDING; PROTEIN STRUCTURE, SECONDARY; RANK LIGAND; RECEPTORS, CALCITRIOL; RNA, MESSENGER; STEREOISOMERISM;

EID: 44749091071     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.05.041     Document Type: Article

References (21)

1. Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., Teepe M.C., DuBose R.F., Cosman D., and Galibert L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390 (1997) 175-179
2. Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M., Kalachikov S., Cayani E., Bartlett III F.S., Frankel W.N., Lee S.Y., and Choi Y. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272 (1997) 25190-25194
3. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., and Boyle W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
4. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., Higashio K., Udagawa N., Takahashi N., and Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95 (1998) 3597-3602
5. Rochel N., Wurtz J.M., Mitschler A., Klaholz B., and Moras D. The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol. Cell 5 (2000) 173-179
6. Moras D., and Gronemeyer H. The nuclear receptor ligand-binding domain: structure and function. Curr. Opin. Cell Biol. 10 (1998) 84-391
7. Carlberg C. Molecular basis of the selective activity of vitamin D analogues. J. Cell. Biochem. 88 (2003) 274-281
8. Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M.T., and Martin T.J. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20 (1999) 345-357
9. 3 antagonist. Bioorg. Med. Chem. Lett. 14 (2004) 2579-2583
10. 3-26,23-lactams. Designed on the basis of the helix 12-folding inhibition hypothesis. J. Med. Chem. 49 (2006) 2398-2406
11. 3 induces differentiation of human myeloid leukemia cells. Biochem. Biophys. Res. Commun. 102 (1981) 937-943
12. 3-26,23-lactone in inducing differentiation of human myeloid leukemia cells. Arch. Biochem. Biophys. 220 (1983) 90-94
13. Miyaura C., Inada M., Matsumoto C., Ohshiba T., Uozumi N., Shimizu T., and Ito A. An essential role of cytosolic phospholipase A2α in prostaglandin E2-mediated bone resorption associated with inflammation. J. Exp. Med. 197 (2003) 1303-1310
14. 2 production by osteoblast plays a critical role in lipopolysaccharide-induced bone loss associated with inflammation. J. Immunol. 177 (2006) 1879-1885
15. Yoshizawa T., Handa Y., Uematsu Y., Takeda S., Sekine K., Yoshihara Y., Kawakami T., Arioka K., Sato H., Uchiyama Y., Masushige S., Fukamizu A., Matsumoto T., and Kato S. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat. Genet. 16 (1997) 391-396
16. 3 from pagetic bone marrow cells. J. Steroid Biochem. Mol. Biol. 89-90 (2004) 331-334
17. 3. Endocrinology 142 (2001) 59-67
18. 3 selectively induces bone formation. Proc. Natl. Acad. Sci. USA 99 (2002) 13487-13491
19. Ke H.Z., Qi H., Crawford D.T., Simmons H.A., Xu G., Li M., Plum L., Clagett-Dame M., DeLuca H.F., Thompson D.D., and Brown T.A. A new vitamin D analog, 2MD, restores trabecular and cortical bone mass and strength in ovariectomized rats with established osteopenia. J. Bone Miner. Res. 20 (2005) 1742-1755
20. Plum L.A., Fitzpatrick L.A., Ma X., Binkley N.C., Zella J.B., Clagett-Dame M., and DeLuca H.F. 2MD, a new anabolic agent for osteoporosis treatment. Osteoporos. Int. 17 (2006) 704-715
21. Uchiyama Y., Higuchi Y., Takeda S., Masaki T., Shiraishi A., Sato K., Kubodera N., Ikeda K., and Ogata E. ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone 30 (2002) 582-588